For more information about the Heart Failure Network trials, please use the links provided. These links will open a new window to the National Institutes of Health website: www.clinicaltrials.gov/
LIFE (Entresto-TM (LCZ696) In Advanced Heart FailurE)
The purpose of LIFE is to test whether LCZ696, a newly approved drug for heart failure that combines sacubitril and valsartan, improves symptoms and outcomes in persons with advanced heart failure in comparison to treatment with valsartan alone over 24 weeks. Enrollment is ongoing.
SUBQ-HF (Subcutaneous Furosemide in Acute Decompensated Heart Failure)
The purpose of SUBQ-HF is to evaluate a strategy of early discharge with daily subcutaneous furosemide using a novel delivery device compared to usual care in both outpatients and patients hospitalized for acute heart failure after initial stabilization. Enrollment is ongoing